عنوان مقاله [English]
Introduction: This study is a clinical trial with trial ID 4N20171228038109, which aimed to evaluate the effectiveness of paroxetine on social anxiety disorder.
Materials and Methods: The statistical population of this study included all those referring to psychiatric services and private psychiatric offices diagnosed with social anxiety disorder in Mashhad city during the years 1396-96 in Specialized Psychological Center. In the current study, 24 of these patients were selected by purposive sampling and were randomly assigned to the groups. Research variables were measured by Spin Social Anxiety Inventory (2000), Beck Depression Inventory, World Health Organization Short Form Quality of Life Scale (1989), and Wilson & Rappi (2005) Social Negative Events Consequences. And evaluated 3 months after drug treatment with paroxetine.
Results: Statistical analysis of current research data using repeated measures ANOVA showed that in general, paroxetine was significantly (p <0.05) effective on the dependent variables.
Conclusion: Paroxetine was significantly effective in the post-test phase on most of the components of the dependent variables and was not statistically significant in the follow-up phase. The control group also showed no significant difference in the three stages of the test.
1- Tiwari N, Baldwin. DS. Yogic Breathing Techniques in the Management of Anxiety and Depression: Systematic Review of Evidence of Efficacy and Presumed Mechanism of Action. Anxiety. (2018) 320- 228.
2- Kessler,R. C., Chiu,W. T., Demler,O., & Walters, E. E.. Prevalence, severity, and comorbidity of 12–month DSM–IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, (2015)62, 617–627.
3- Stephen, S., Gottlieb, M.D. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. American Heart Journal, (2007)153(5),868-873
4- Morgan B, Hoff. LA. psychiatric and mental health Essentials in primary care. (2011). 698 wH, editor. new york
5- Gustavsson. A, Svensson. M, Jacobi F. Cost of disorders of the brain in Europe. Eur Neuropsychopharmacol. (2011)21: 718: 779.
6- Martinez-Martin. P, Rojo-Abuin. J.M, Dujardin. K, Pontone. G.M, Forjaz. M.J, Starkstein. S, Leentjens. A.F. Designing a new scale to measure anxiety symptoms in Parkinson’s disease: item selection based on canonical correlation analysis. European Journal of Neurology. (2013)11-23.
7- Allen F, Fisher M, Phipps N. The correlation between depression and diabetes. US Pharma.)2014(39(10):12-15.
8- Stefanova. E, Ziropadja. L, Petrovic. M, Stojkovic. T. Screening for anxiety symptoms in Parkinson disease: a cross-sectional study. J Geriatr Psychiatry Neurol. (2013)26 (1) 34-40.
9- Dozeman. E, , van Schaik, J. H. (2011). Feasibility and effectiveness of activityscheduling as a guided self-help intervention for the prevention of depression and anxiety in residents in homes for the elderly: a pragmatic randomized controlled trial. International Psychogeriatrics Association. 23 (6): 969–78
10- Susan, H. S., Ronald. M. R. (2016). Behavior Research and Therapy ؛The etiology of social anxiety disorder .An evidence – based model , 1100-1109.
11- Kishi T, Matsuda Y, Matsunaga S, et al. Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial. Neuropsychiatr Dis Treat. 2017;13:117–125. [PMC free article] [PubMed]
12- Tempei O, Yoshinori W, Seiji H& Toshiaki k.9(2018) Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study. Neuropsychiatr Dis Treat. 2018; 14: 955–966. Published online Apr 6. doi: 10.2147/NDT.S152985
13- Kubzansky. k. Going to the heart of the matter: Do nagative emotions cause Coronary Artery disease psychosomatic research. (2018)48 (4): 337-23.
14- Michael, A. S., Amy .M. L., Boris.B. B., Emily R. G., & Irving K. (2014). The Efficacy of Paroxetine and Placebo in Treating Anxiety and Depression: A Meta-Analysis of Change on the Hamilton Rating Scales. Plosone. Volume 9, Issue 8, e106337
15- Harmer CJ, O’Sullivan U, Favaron E, Massey-Chase R, Ayres R, Reinecke A, Goodwin GM, Cowen PJ(2019): Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry; 166:1178–1184
16- Karl Rickels, M.D, Rocco Zaninelli, M.D. James McCafferty, B.S(2013). Paroxetine Treatment of Generalized Anxiety Disorder:A Double-Blind, Placebo-Controlled Study . Am J Psychiatry 160:4, April 2003749Articlehttp
17- Wagner KD, Berard R, Stein MB,et al(2014). A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in childrenand adolescents with social anxiety disorder.Arch Gen Psychiatry;61:1153–62
18- Olfson M, Kroenke K. Wang S, Blanco C(2014). Trends in office-based mental health care provided by psychiatrists and primary care physicians. J Clin Psychiatry. 75: 247-253